Investigational agents for sickle cell disease

Bibliography

• INGRAM VN: Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin. Nature (1957) 180:326-328.
   PubMed Web of Science ®Google Scholar
• OKPALA I: Epidemiology, genetics and pathophysiology of sickle cell disease. In: Practical management of haemoglobinopathies, Okpala I (Ed.), Blackwell Publishing, Oxford, UK (2004):20-25.
   Google Scholar
• UNESCO: Sickle cell anaemia, a public health priority. Report of Commission II, General Conference, 33rd Session, Paris, France (2005).
   Google Scholar
• KONOTEY-AHULU FID: Hereditary qualitative and quantitative erythrocyte defects in Ghana: an historical and geographical survey. Ghana Med. J. (1968) 7:118-119.
   Google Scholar
• ONWUBALILI JK: Sickle cell anaemia: an explanation for the ancient myth of reincarnation in Nigeria. Lancet (1983) 322:503-505.
   Google Scholar
• AFRICANUS HORTON JB: The diseases of tropical climates and their treatment. Churchill, London, UK (1874).
   Google Scholar
• HERRICK JB: Peculiar elongated and sickled red blood corpuscles in a case of severe anaemia. Arch. Intern. Med. (1910) 6:517-521.
   Google Scholar
• OKPALA I: New therapies for sickle cell disease. Hematol. Oncol. Clin. N. Am. (2005) 19:975-987.
   PubMed Web of Science ®Google Scholar
• STUART MJ, NAGEL R: Sickle cell disease. Lancet (2004) 364:1343-1360.
   PubMed Web of Science ®Google Scholar
• CHARACHE S: Mechanisms of action of hydroxyurea in sickle cell anaemia in adults. Semin. Hematol. (1997) 34:15-21.
   PubMed Web of Science ®Google Scholar
• COKIC VP, SMITH RD, BELESLIN-COKIC BB et al.: Hydroxyurea induces fetal hemoglobin by nitric-oxide dependent activation of soluble guanyl cyclase. J. Clin. Invest. (2003) 111:231-239.
   PubMed Web of Science ®Google Scholar
• STYLES LA, LUBIN B, VICHINSKY E et al.: Decrease of very late activation antigen-4 and CD36 expression on reticulocytes in sickle cell patients treated with hydroxyurea. Blood (1997) 89:2554-2559.
   PubMed Web of Science ®Google Scholar
• HILLERY CA, DU MC, WANG WC, SCOTT JP: Hydroxyurea therapy decreases in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Br. J. Haematol. (2000) 109:322-327.
   PubMed Web of Science ®Google Scholar
• STEINBERG MH, BARTON F, CASTRO O et al.: Effect of hydroxyurea on mortality and morbidity in sickle cell anemia. J. Am. Med. Assoc. (2003) 289:1645-1651.
   PubMed Web of Science ®Google Scholar
• JOHNSTON Jr RB, HEWMAN SL, STRUTH AC: An abnormality of the alternative pathway of complement activation in sickle cell disease. N. Engl. J. Med. (1973) 288:803-805.
   PubMed Web of Science ®Google Scholar
• PEARSON HA: The kidney, hepatobiliary system, and spleen in sickle cell anaemia. Ann. NY Acad. Sci. (1989) 565:120-125.
   PubMed Web of Science ®Google Scholar
• MOLLAPOUR E, PORTER JB, KACMARSKI R et al.: Raised neutrophil phospholipase A2 activity and defective priming of NADPH oxidase and phospholipase in sickle cell disease. Blood (1998) 91:3423-3429.
   PubMed Web of Science ®Google Scholar
• ANYAEGBU CC, OKPALA IE, AKEN’OVA AY et al.: Peripheral blood neutrophil count and candidicidal activity correlate with the clinical severity of sickle cell anaemia. Eur. J. Haematol. (1998) 60:267-268.
   PubMed Web of Science ®Google Scholar
• SAUNTHARARAJAH Y, HILLERY CA, LAVELLE D et al.: Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and haemopoietic differentiation in patients with sickle cell disease. Blood (2003) 102:3865-3870.
   PubMed Web of Science ®Google Scholar
• ABDULMALIK O, SAFO MK, CHEN Q et al.: 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br. J. Haematol. (2005) 128:552-561.
   PubMed Web of Science ®Google Scholar
• ABDULMALIK O, SAFO MK, JOSHI G et al.: In vitro anti-sickling effects of novel pyridyl derivatives with enhanced potency. Blood (2005) 106:666a (Supplement).
   Google Scholar
• SAFO MK, ABDULMALIK O, DANSO-DANQUAH R et al.: Structural basis for the potent antisickling effect of a novel class of five-membered heterocyclic aldehydic compounds. J. Med. Chem. (2004) 47:4665-4676.
   PubMed Web of Science ®Google Scholar
• ABRAHAM DJ, MEHANNA AS, WIREKO FC, WHITNEY J, THOMAS RP, ORRINGER EP: Vanillin, a potential agent for the treatment of sickle cell anemia. Blood (1991) 77:1334-1341.
   PubMed Web of Science ®Google Scholar
• BEDDELL CR, GOODFORD PJ, KNEEN G, WHITE RD, WILKINSON S, WOOTTON R: Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes. Br. J. Pharmacol. (1984) 82:397-407.
   PubMed Web of Science ®Google Scholar
• KEIDAN AJ, FRANKLIN IM, WHITE RD, JOY M, HUEHNS ER, STUART J: Effect of BW12C on oxygen affinity of haemoglobin in sickle cell disease. Lancet (1986) 1:831-834.
   PubMed Web of Science ®Google Scholar
• VAN-GORSEL H, LI C, KERBEL EL, SMITS M, KADER AA: Compositional characterization of prune juice. J. Agric. Food Chem. (1992) 40:784-789.
   Web of Science ®Google Scholar
• WAMBEBE CO, AFOLABI BE, BADRU BO et al.: Efficacy of niprisan in the prophylactic management of patients with sickle cell disease. Curr. Ther. Res. (2001) 62:26-34.
   Web of Science ®Google Scholar
• IYAMU EW, TURNER EA, ASAKURA T: In vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent anti-sickling agent. Br. J. Haematol. (2002) 118:337-343.
   PubMed Web of Science ®Google Scholar
• IYAMU EW, TURNER EA, ASAKURA T: Niprisan (Nix-0699) improves the survival rates of transgenic sickle cell mice under acute severe hypoxic conditions. Br. J. Haematol. (2003) 122:1001-1008.
   PubMed Web of Science ®Google Scholar
• WAMBEBE C, KHAMOFU H, MOMOH JA et al.: Double-blind, placebo-controlled, randomised cross-over trial of NIPRISAN in patients with sickle cell disorders. Phytomedicine (2001) 8:252-261.
   PubMed Web of Science ®Google Scholar
• XECHEM INTERNATIONAL: Update on Niprisan: Nix-0699. Press release made at 27th Annual Meeting of National Sickle Cell Program, Los Angeles, USA (April 2004).
   Google Scholar
• TAN P, LUSCINKAS FW, HOMER-VANNIASINKAMS S: Cellular and molecular mechanisms of inflammation and thrombosis. Eur. J. Vasc. Endovasc. Surg. (1999) 17:373-389.
   PubMed Web of Science ®Google Scholar
• EMBURY SH, MATSUI NM, RAMANUJAM S et al.: The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo. Blood (2004) 104:3378-3385.
   PubMed Web of Science ®Google Scholar
• VON ADRIAN UH, CHAMBERS JD, McEVOY LM et al.: Two-step model of leukocyte-endothelial interactions in inflammation: distinct roles for LECAM-1 and leukocyte β2-integrins in vivo. Proc. Natl. Acad. Sci. USA (1991) 88:7538-7542.
   PubMed Web of Science ®Google Scholar
• OKPALA I: Leukocyte adhesion and the pathophysiology of sickle cell disease. Curr. Opin. Hematol. (2006) 13:40-44.
   PubMed Web of Science ®Google Scholar
• CHIANG EY, FRENETTE PS: Sickle cell vaso-occlusion. Hematol. Oncol. Clin. N. Am. (2005) 19:771-784.
   PubMed Web of Science ®Google Scholar
• KAUL DK, FABRY ME, NAGEL RL: Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: pathophysiological implications. Proc. Natl. Acad. Sci. USA (1989) 86:3356-3360.
   PubMed Web of Science ®Google Scholar
• OKPALA I: The intriguing contribution of white blood cells to sickle cell disease: a red cell disorder. Blood Rev. (2004) 18:65-73.
   PubMed Web of Science ®Google Scholar
• OKPALA IE, DANIEL Y, HAYNES R et al.: Relationship between the clinical manifestations of sickle cell disease and the expression of adhesion molecules on white blood cells. Eur. J. Haematol. (2002) 69:135-144.
   PubMed Web of Science ®Google Scholar
• OKPALA IE, DANIEL Y, HAYNES R et al.: High expression of αMβ2 integrin and L-selectin by leukocytes of patients with severe manifestations of sickle cell disease. Blood (2002) 100:11a (Supplement).
   PubMed Web of Science ®Google Scholar
• HEBBLE RP, OSAROGIAGBON R, KAUL D: The endothelial biology of sickle cell disease: inflammation and chronic vasculopathy. Microcirculation (2004) 11:129-151.
   PubMed Web of Science ®Google Scholar
• KAUL DK, LIU X, CHOONG S et al.: Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. Am. J. Physiol. Heart Circ. Physiol. (2004) 287:H293-H301.
   PubMed Web of Science ®Google Scholar
• BELCHER JD, MARKER PH, WEBER JP et al.: Activated monocytes in sickle cell disease: potential role in activation of vascular endothelium and vaso-occlusion. Blood (2000) 96:2451-2459.
   PubMed Web of Science ®Google Scholar
• McEVER RP: Selectins: lectins that initiate cell adhesion under flow. Curr. Opin. Cell Biol. (2002) 14:581-586.
   PubMed Web of Science ®Google Scholar
• MATSUI NM, BORSIG L, ROSEN SD et al.: P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. Blood (2001) 98:1955-1962.
   PubMed Web of Science ®Google Scholar
• HICKS AER, NOLAN SL, RIDGER VC et al.: Recombinant P-selectin glycoprotein ligand-1 inhibits leukocyte rolling by all 3 selectins in vivo: complete inhibition of rolling is not required for anti-inflammatory effect. Blood (2003) 101:3249-3256.
   PubMed Web of Science ®Google Scholar
• LEW VL, BOOKCHIN RM: Ion transport pathology in the mechanism of sickle cell dehydration. Physiol. Rev. (2005) 85:179-200.
   PubMed Web of Science ®Google Scholar
• STEINBERG MH, RODGERS GP: Pathophysiology of sickle cell disease: role of cellular and genetic modifiers. Semin. Hematol. (2001) 38:299-306.
   PubMed Web of Science ®Google Scholar
• DE FRANCESCHI L, SAADANE N, TRUDEL M et al.: Treatment with oral clotrimazole blocks Ca2+ mediated K+ transport and reverses erythrocyte dehydration in transgenic SAD mice: a model for therapy of sickle cell disease. J. Clin. Invest. (1994) 93:1670-1676.
   PubMed Web of Science ®Google Scholar
• STOCKER JW, DE FRANCESCHI L, McNAUGHTON-SMITH GA et al.: ICA-17043 a novel Gardos channel blocker, prevents sickle red blood cell dehydration in vitro and in vivo in SAD mice. Blood (2003) 101:2412-2418.
   PubMed Web of Science ®Google Scholar
• ATAGA KI, DE CASTRO LM, SWERDLOW P et al.: Efficacy and safety of the Gardos channel inhibitor, ICA-17043, in patients with sickle cell anemia. Blood (2004) 104:33a (Supplement).
   Google Scholar
• SADELAIN M: Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia. Curr. Opin. Hematol. (2006) 13:142-148.
   PubMed Web of Science ®Google Scholar
• PUTHENVEETIL G, MALIK P: Gene therapy for hemoglobinopathies: are we there yet? Curr. Hematol. Rep. (2004) 3:298-305.
   PubMedGoogle Scholar
• HOPPE CC, WALTERS MC: Bone marrow transplantation in sickle cell anemia. Curr. Opin. Oncol. (2001) 13:85-90.
   PubMed Web of Science ®Google Scholar
• AMROLIA P, ALMEIDA A, HALSEY C, ROBERTS IA, DAVIES SC: Therapeutic challenges in childhood sickle cell disease. Br. J. Haematol. (2003) 120:725-736.
   PubMed Web of Science ®Google Scholar
• PAWLIUK R, WESTERMAN KA, FABRY ME et al.: Correction of sickle cell disease in transgenic mouse models by gene therapy. Science (2001) 294:2368-2371.
   PubMed Web of Science ®Google Scholar
• KOHN DB, SADELAIN M, GLORIOSO JC: Occurrence of leukaemia following gene therapy of X-linked SCID. Nat. Rev. Cancer (2003) 3:477-488.
   PubMed Web of Science ®Google Scholar
• SADELAIN M: Insertional oncogenesis in human gene therapy: how much of a risk? Gene Ther. (2004) 11:567-573.
   Web of Science ®Google Scholar
• OHENE-FREMPONG K: Indications for red cell transfusion in sickle cell disease. Semin. Hematol. (2001) 38:5-13.
   PubMedGoogle Scholar
• THE INVESTIGATORS FORICL670 STUDY 109: A randomised, controlled, Phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once-daily oral iron chelator deferasirox (Exjade, ICL670) is well tolerated and reduces iron burden. Blood (2005) 106:95a (Supplement).
   PubMed Web of Science ®Google Scholar
• CABANTCHIK ZI, LINK G, GLICKSTEIN H et al.: Deferasirox (Exjade, ICL670): a journey into labile iron centers of living cardiomyocytes. Blood (2005) 106:243a (Supplement).
   Google Scholar
• BRISSOT P, TURLIN B, FORNI GL et al.: Iron chelation therapy with deferasirox (Exjade, ICL670) or deferioxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion-dependent anemia. Blood (2005) 106:242a (Supplement).
   Google Scholar
• COHEN A, MASERA G, ZOUMBOS N et al.: Effect of iron intake on control of body iron in patients with thalassaemia major treated with deferasirox (Exjade). Blood (2005) 106:242a (Supplement).
   Web of Science ®Google Scholar
• MANTADAKIS E, CAVENDER JD, ROGERS ZR et al.: Prevalence of priapism in boys with sickle cell anemia. J. Pediatr. Hematol. Oncol. (1999) 21:518-522.
   PubMed Web of Science ®Google Scholar
• LUE TF: Physiology of penile erection and pathophysiology of erctile dysfunction and priapism. In: Campbell’s Urology, Walsh PC, Retik AB, Vaughan Jr ED et al. (Eds), WB Saunders, Philadelphia, USA (2002) 8:1591-1613.
   Google Scholar
• OKPALA I, WESTERDALE N, JEGEDE T, CHEUNG B: Etilefrine for the prevention of priapism in adult sickle cell disease. Br. J. Haematol. (2002) 118:918-921.
   PubMed Web of Science ®Google Scholar
• ROGERS ZR: Priapism in sickle cell disease. Hematol. Oncol. Clin. N. Am. (2005) 19:917-928.
   PubMed Web of Science ®Google Scholar
• WINTER CC, McDOWELL G: Experience with 105 patients with priapism: update review of all aspects. J. Urol. (1988) 140:980-983.
   PubMed Web of Science ®Google Scholar
• DRUGDEX SYSTEM: Etilefrine. Volume 122. Thompson MICROMEDEX, Greenwood Village, Colorado, USA (2004).
   Google Scholar
• VIRAG R, BACHIR D, LEE K et al.: Preventive treatment of priapism in sickle cell disease with oral and self-administered intracavernous injection of etilefrine. Urology (1996) 47:777-781.
   PubMed Web of Science ®Google Scholar
• GBADOE AD, ATAKOUMA Y, KUSIAKU K et al.: Management of sickle cell priapism with etilefrine. Arch. Dis. Child. (2001) 85:52-53.
   PubMed Web of Science ®Google Scholar
• ADEYOJU AB, OLUJOHUNGBE ABK, MORRIS J et al.: Priapism in sickle cell disease: incidence, risk factors and complications-an international multicenter study. Br. J. Urology Int. (2002) 90:898-902.
   Web of Science ®Google Scholar
• OKPALA I: Pulmonary hypertension: a complication of haemolytic states. In: Practical management of haemoglobinopathies, Okpala I (Ed.), Blackwell Publishing, Oxford, UK (2004):130-133.
   Google Scholar
• CASTRO O, GLADWIN MT: Pulmonary hypertension in sickle cell disease: mechanisms, diagnosis, and management. Hematol. Oncol. Clin. N. Am. (2005) 19:881-896.
   PubMed Web of Science ®Google Scholar
• CASTRO O: Systemic fat embolism and pulmonary hypertension in sickle cell disease. Hematol. Oncol. Clin. N. Am. (1996) 10:1289-1303.
   PubMed Web of Science ®Google Scholar
• ATAGA KI, SOOD N, DE GENT G et al.: Pulmonary hypertension in sickle cell disease. Am. J. Med. (2004) 117:665-669.
   PubMed Web of Science ®Google Scholar
• VICARI P, ROSARIO CAVALHEIRO RC, DE GOUVEIA A et al.: Echocardiographic abnormalities in Brazilian sickle cell patients. Am. J. Hematol. (2005) 78:160-161.
   PubMed Web of Science ®Google Scholar
• ONYEKWERE O, CAMPBELL A, TESHOME M et al.: Prevalence of pulmonary hypertension (PHTN) in sickle cell disease (SCD) adolescents with pulmonary complications. 28th Annual Meeting of the National Sickle Cell Program, Cincinnati, USA (2005) (Abstract).
   Google Scholar
• WALI YA, VENUGOPALAN P, RIVERA E et al.: Cardiovascular function in Omani children with sickle cell anaemia. Ann. Trop. Paediatr. (2000) 20:243-246.
   PubMed Web of Science ®Google Scholar
• JOHNSON CS, GIORGIO AJ: Arterial blood pressure in adults with sickle cell disease. Arch. Intern. Med. (1981) 141:891-893.
   PubMed Web of Science ®Google Scholar
• HAMMOND TG, MOSESSON MW: Fat small bowel necrosis and pulmonary hypertension in sickle cell disease. Arch. Intern. Med. (1989) 149:447-448.
   PubMed Web of Science ®Google Scholar
• EL-BESHLAWY A, ABDELAOUFF E, BEBAWY I: Pulmonary hypertension in sickle cell disease. Abstract Book of the 25th Meeting of the International Society of Haematology-African & European Division, Durban, South Africa (1999):120.
   Google Scholar
• MORRIS CR, HAGAR W, VAM WARMERDAM J et al.: Arginine therapy improves pulmonary artery pressures in patients with sickle cell disease and pulmonary hypertension. Blood (2002) 100:452a (Supplememt).
   Google Scholar